Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly ...

Deutsche Bank analyst Justin Bowers raised the firm’s price target on Bio-Techne (TECH) to $72 from $66 and keeps a Buy rating on the shares. The ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

With its stock down 6.6% over the past month, it is easy to disregard Bio-Techne (NASDAQ:TECH). However, stock prices are usually driven by a company’s financials over the long term, which in this ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...